Is Veradermics (MANE) Undervalued On Its Pullback From A Strong 2026 Run?

Veradermics (MANE) drew fresh attention after its recent share move, with the stock closing at $128.60. That price now anchors investor focus on the biopharma group’s dermatology pipeline and valuation.

The recent pullback, with a 1-day share price return down 5.79% and a 7-day share price return down 10.60%, comes after Veradermics logged a 30-day share price return of 18.02% and a year-to-date share price return of 240.66%. This indicates that momentum has cooled in the very short term, while the longer trend remains strong.

Scan how Veradermics compares to other high momentum biotech stories and widen your watchlist with 21 high quality undiscovered gems before the next wave of clinical updates hits.

After a surge that left Veradermics up more than 200% this year, yet still sitting below analyst targets and intrinsic estimates, does the current pullback tilt the risk reward toward fresh buyers or caution?

Most Popular Narrative: 25% Undervalued

With Veradermics closing at $128.60 against a widely followed fair value of $170.50, the current pullback sits inside a story that assumes a long path from zero revenue today to a fully built hair loss franchise in the next few years.

Expanding focus on pattern hair loss in women, who currently have no FDA approved oral prescription treatments despite representing around 30 million people in the U.S., creates a large addressable pool of new patients that could support future revenue growth if Veradermics converts this unmet demand into paid therapy adoption.

See why 3 investors see Veradermics as 25% undervalued.

Result: Fair Value of $170.50 (UNDERVALUED)

Still, Veradermics remains a zero revenue, loss making biotech, and any disappointment in late stage hair loss data or tolerance for a very high future P/E could quickly pressure sentiment.

Find out about the key risks to this Veradermics narrative.

Next Steps

If this mix of optimism and caution around Veradermics feels familiar, treat it as a prompt to move fast, check the numbers, and decide where you stand based on the 3 key rewards and 3 important warning signs.

Looking for more investment ideas beyond Veradermics?

Do not stop with one ticker. Broaden your watchlist using focused screens that surface different types of opportunities and help you avoid chasing the same crowded stories.

• Target potential mispricings by scanning companies that combine quality, fundamentals and attractive entry points through the 42 high quality undervalued stocks.
• Strengthen your income stream by reviewing businesses with robust payouts and higher yields via the 6 dividend fortresses.
• Guard your capital by filtering for resilient businesses with sturdier financial profiles using the 32 resilient stocks with low risk scores.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com